Does Rallies show 13F holders for ONC?

Yes. Rallies tracks hedge fund and 13F ownership data for ONC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ONC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ONC. It does not provide personalized investment advice.

ONC (BeOne Medicines Ltd. American Depositary Shares) Stock Analysis - Hedge Fund Holdings

BeOne Medicines Ltd. American Depositary Shares (ONC) is a publicly traded Healthcare sector company. As of May 21, 2026, ONC trades at $309.42 with a market cap of $30.41B and a P/E ratio of 853.25. ONC moved +3.95% today. Year to date, ONC is -3.61%; over the trailing twelve months it is +30.35%. Its 52-week range spans $172.67 to $385.22. Analyst consensus is strong buy with an average price target of $388.58. Rallies surfaces ONC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ONC stock?

Hedge funds tracked by Rallies that own ONC include Temasek Holdings, Panagora Asset, Rokos Capital, Farallon Capital, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BeOne Medicines Ltd. American Depositary Shares.

ONC Key Metrics

Key financial metrics for ONC
Metric	Value
Price	$309.42
Market Cap	$30.41B
P/E Ratio	853.25
EPS	$0.36
Dividend Yield	0.00%
52-Week High	$385.22
52-Week Low	$172.67
Volume	6.54K
Avg Volume	0
Revenue (TTM)	$5.74B
Net Income	$513.02M
Gross Margin	88.31%

Top Hedge Funds Holding ONC

Temasek Holdings holds 862.64K shares of ONC, changed -6.19% as of Mar 31, 2026.
Panagora Asset holds 57.32K shares of ONC, changed +74.01% as of Mar 31, 2026.
Rokos Capital holds 14.34K shares of ONC, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 1.10K shares of ONC, changed +0.00% as of Mar 31, 2026.
Bridgewater Associates holds 772 shares of ONC, changed -52.05% as of Mar 31, 2025.

Latest ONC News

BeOne Medicines jumps on Q1 beat, higher 2026 outlook and BRUKINSA momentum — May 6, 2026
BeOne Medicines slides as traders de-risk into May 6 results date — Apr 23, 2026
BeOne Medicines (ONC) climbs as traders position for Q1 earnings after-close — Apr 15, 2026
BeOne Medicines jumps as China grants conditional approval to SCLC therapy — Apr 14, 2026
BeOne Medicines jumps as Wolfe Research initiates with Outperform, $340 target — Apr 8, 2026

Recent ONC Insider Trades

Lee Chan Henry sold 332 (~$103.16K) on May 13, 2026.
Lee Chan Henry sold 332 (~$103.45K) on Apr 8, 2026.
Lee Chan Henry sold 341 (~$102.30K) on Mar 11, 2026.

ONC Analyst Consensus

12 analysts cover ONC: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $388.58.

Common questions about ONC

Who owns ONC stock?: Hedge funds tracked by Rallies that own ONC include Temasek Holdings, Panagora Asset, Rokos Capital, Farallon Capital, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BeOne Medicines Ltd. American Depositary Shares.
Does Rallies show 13F holders for ONC?: Yes. Rallies tracks hedge fund and 13F ownership data for ONC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ONC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ONC. It does not provide personalized investment advice.